Table 3.

Morphologic and molecular tumor characteristics before imatinib therapy (per protocol)

Patient IDTumor typeCOL1A1–PDGFBLocalization (tissue layers involved)CD34S100VascularizationHemorrhagesCellular/nuclear pleomorphismKi67Mitoses
ADO-01DFSPNEDermis + subcutisPositive (homogeneous)NegativeModerateSeveralNone/none5%None
ADO-02DFSPNEDermis + subcutis + sceletal musclesPositive (homogeneous)NegativeHighNoneNone/moderateNDNone
ADO-03DFSPNDSubcutisPositive (heterogeneous)NegativeLowNoneNone/moderate–highNDSeveral
ADO-04DFSP-FSPositive (RT-PCR + sequencing, FISH)Dermis + subcutisPositive (homogeneous)NegativeModerateNoneLow–moderate/none6%Sporadic
ADO-05DFSPPositive (RT-PCR + sequencing)Dermis + subcutisPositive (homogeneous)NegativeModerateNoneNone/none2%None
ADO-06DFSP, myxoid typePositive (RT-PCR + sequencing, FISH)Dermis + subcutisPositive (homogeneous)NegativeModerateNoneLow/none3%None
ADO-07DFSP-FS, pigmented typePositive (RT-PCR + sequencing, FISH)Dermis + subcutisPositive (heterogeneous)Positive (heterogeneous)HighNoneModerate/moderate–highNDSporadic
ADO-09DFSP, pigmented-typeNDDermis + subcutisPositive (homogeneous)NegativeLowNoneNone/noneNDNone
ADO-10DFSPNegative (RT-PCR + sequencing)Dermis + subcutisPositive (homogeneous)NDModerateNoneNone/none4%None
ADO-11DFSPPositive (RT-PCR + sequencing)Dermis + subcutisPositive (homogeneous)NegativeModerateNoneNone/none4%None
ADO-12DFSPNDDermis + subcutis + deep soft tissue + bonePositive–negative (heterogeneous)NegativeHighNumerousNone/none5%None
ADO-13DFSPNegative (FISH)Dermis + subcutisPositive (homogeneous)NegativeModerateNoneLow/none8%Sporadic
ADO-15DFSPNEDermis + subcutisPositive (homogeneous)NegativeLowNoneModerate/none2%None
ADO-16DFSPNegative (RT-PCR + sequencing)Dermis + subcutisPositive (homogeneous)NDModerateNoneLow/none2%Several

NOTE: Morphologic and molecular tumor characteristics as analyzed in the per protocol population, for details see Patients and Methods.

Abbreviations: ND, not done; NE, not evaluable.